To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding biologic and biosimilar products, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Representative for Maryland's 3rd congressional district. Democrat.
Last Updated: Jul 23, 2018
Length: 8 pages
115th Congress, 2017–2019
This bill was introduced on July 23, 2018, in a previous session of Congress, but was not enacted.
Jul 23, 2018
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
H.R. 6478 (115th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2019). H.R. 6478 — 115th Congress: Biosimilars Competition Act of 2018. Retrieved from https://www.govtrack.us/congress/bills/115/hr6478
“H.R. 6478 — 115th Congress: Biosimilars Competition Act of 2018.” www.GovTrack.us. 2018. October 19, 2019 <https://www.govtrack.us/congress/bills/115/hr6478>
Biosimilars Competition Act of 2018, H.R. 6478, 115th Cong..
|title=H.R. 6478 (115th)
|accessdate=October 19, 2019
|author=115th Congress (2018)
|date=July 23, 2018
|quote=Biosimilars Competition Act of 2018
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.